Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Future Of Bankrupt Orchid In Doubt

Indian Appeal Body Rejects Dhanuka Rescue Of Orchid

Executive Summary

An Indian appellate tribunal has scuttled the acquisition of bankrupt Orchid Pharma by Dhanuka Labs, ruling that the deal contravened the country’s bankruptcy code.

You may also be interested in...

India’s Dhanuka Wins Race To Take Over Bankrupt Orchid

India’s Dhanuka Laboratories has won the race for bankrupt Orchid Pharma after the National Company Law Tribunal decided the firm’s offer was better than two rival bids.

India’s Orchid Pharma Is Back On The Market

An acrimonious end to a takeover bid for bankrupt Indian player Orchid Pharma has reopened the pathway for previously interested parties to table fresh bids.

How India's Orchid failed to bloom

You probably know that things are rather bleak when prominent investors openly slam a company's management. That's if a huge debt pile up hasn't already sent alarm bells ringing.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts